Validation and clinical evaluation of a SARS-CoV-2 surrogate virus neutralisation test (sVNT)
| Autor: | Nicolas Vuilleumier, Marieke Hoogerwerf, Sabine Yerly, Giulia Torriani, Fion Brouwer, Isabella Eckerle, Benjamin Meyer, Chantal Reusken, Johan Reimerink, Gert Jan Godeke, Laurent Kaiser |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Male Epidemiology Betacoronavirus/genetics/immunology ddc:616.07 Antibodies Viral Viral/blood Neutralization Drug Discovery Medicine Viral/blood/virology neutralising antibodies ddc:616 biology General Medicine Middle Aged Vaccination pseudovirus neutralisation assay Titer Infectious Diseases surrogate virus neutralisation assay Female Antibody Coronavirus Infections Research Article Adult Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 030106 microbiology Pneumonia Viral Immunology Context (language use) Enzyme-Linked Immunosorbent Assay Microbiology Virus Antibodies Neutralizing/blood cell-based virus neutralisation assay 03 medical and health sciences Betacoronavirus Immunity Neutralization Tests Virology Coronavirus Infections/blood/virology Humans Pandemics Aged Neutralization Tests/methods business.industry Enzyme-Linked Immunosorbent Assay/methods SARS-CoV-2 COVID-19 Pneumonia Antibodies Neutralizing 030104 developmental biology biology.protein Parasitology business |
| Zdroj: | Emerging Microbes & Infections article-version (VoR) Version of Record Emerging Microbes & Infections, Vol. 9, No 1 (2020) pp. 2394-2403 |
| ISSN: | 2222-1751 |
| DOI: | 10.1080/22221751.2020.1835448 |
| Popis: | To understand SARS-CoV-2 immunity after natural infection or vaccination, functional assays such as virus neutralising assays are needed. So far, assays to detect SARS-CoV-2 neutralising antibodies rely on cell-culture based infection assays either using wild type SARS-CoV-2 or pseudotyped viruses. Such assays are labour-intensive, require appropriate biosafety facilities and are difficult to standardize. Recently, a new surrogate virus neutralisation test (sVNT) was described that uses the principle of an ELISA to measure the neutralisation capacity of anti-SARS-CoV-2 antibodies directed against the receptor binding domain. Here, we performed an independent evaluation of the robustness, specificity and sensitivity on an extensive panel of sera from 269 PCR-confirmed COVID-19 cases and 259 unmatched samples collected before 2020 and compared it to cell-based neutralisation assays. We found a high specificity of 99.2 (95%CI: 96.9–99.9) and overall sensitivity of 80.3 (95%CI: 74.9–84.8) for the sVNT. Clinical sensitivity increased between early (14 dpos/dpd) from 75.0 (64.7–83.2) to 83.1 (76.5–88.1). Also, higher severity was associated with an increase in clinical sensitivity. Upon comparison with cell-based neutralisation assays we determined an analytical sensitivity of 74.3 (56.4–86.9) and 98.2 (89.4–99.9) for titres ≥10 to |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|